Serial biotech entrepreneur targets obesity with drug fished out of bankruptcy court
A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...
Novo Nordisk's SWOT analysis: obesity drug leader faces supply hurdles
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
Hosted on MSN15h
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
IPWatchdog6h
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
MM&M8h
Hims & Hers set for Super Bowl ad debut highlighting GLP-1 weight loss drugs
Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...
STAT21h
Eli Lilly
Eli Lilly is a top producer of insulin and antibiotics, and a growing force in weight loss drugs and treatments for Alzheimer’s. The company is also known for drugs to treat diabetes (Trulicity ...